Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
Status:
Completed
Trial end date:
2019-03-20
Target enrollment:
Participant gender:
Summary
The study is a randomized, double blinded, vehicle and active comparator controlled, multiple
dose study in subjects with chronic plaque psoriasis. The study will have approximately 15
completers. Each subjects will receive three different topical doses of PF 06763809, PF
06763809 vehicle, and two active comparators. These will be applied to six different
treatment fields for 18 days. The total duration of participation in the study will be
approximately 7 weeks (minimum) to approximately 11 weeks (maximum), including the interval
from Screening to the Follow up phone call visit.